Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 1/20 | 0.45 |
| ▸ | NPC1 | O15118 | 2/20 | 0.45 |
| ▸ | EPHX2 | P34913 | 14/20 | 0.44 |
| ▸ | ALOX5 | P09917 | 13/20 | 0.44 |
| ▸ | HTT | P42858 | 1/20 | 0.42 |
| ▸ | RAB9A | P51151 | 1/20 | 0.42 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.41 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.41 |
| ▸ | ALOX5AP | P20292 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL485193 | 0.91 | KDM4E (0.52) | MAPTNPC1EPHX2ALOX5HTT | |
| SCHEMBL485123 | 0.89 | MAPT (0.45) | MAPTNPC1EPHX2ALOX5HTT | |
| SCHEMBL485979 | 0.89 | MAPT (0.45) | MAPTNPC1EPHX2ALOX5HTT | |
| SCHEMBL485124 | 0.89 | MAPT (0.45) | MAPTNPC1EPHX2ALOX5HTT | |
| SCHEMBL485414 | 0.88 | MAPT (0.45) | MAPTNPC1EPHX2ALOX5HTT | |
| SCHEMBL10289380 | 0.81 | NPC1 (0.45) | MAPTNPC1EPHX2ALOX5RAB9A | |
| SCHEMBL485408 | 0.80 | NPC1 (0.46) | MAPTNPC1EPHX2ALOX5HTT | |
| SCHEMBL485578 | 0.79 | CXCR2 (0.40) | MAPTNPC1EPHX2ALOX5ALOX5AP | |
| SCHEMBL485800 | 0.79 | KMT2A (0.49) | MAPTNPC1EPHX2ALOX5RAB9A | |
| SCHEMBL485257 | 0.78 | EPHX2 (0.45) | MAPTNPC1EPHX2ALOX5RAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8283479-B2 | CXCR2 inhibitors | SANOFI-AVENTIS DEUTSCHLAND GMBH (DE) | 2012-10-09 | — | — | US | disclosed |
| US-20110184177-A1 | CXCR2 INHIBITORS | SANOFI-AVENTIS DEUTSCHLAND GMBH (DE) | 2011-07-28 | — | — | US | disclosed |
| US-7919628-B2 | 2-[(1-Benzyloxy-naphthalene-2-carbonyl)-amino]-2-methyl-propionic acid; inhibitors of chemokine receptors; treatment or prophylaxis of acute and chronic inflammatory diseases such as atherosclerosis, ischemic or reperfusion injuries, chronic obstructive pulmonary disease, asthma, rheumatoid arthritis | SANOFI-AVENTIS DEUTSCHLAND GMBH (DE) | 2011-04-05 | — | — | US | disclosed |
| US-20080090854-A1 | CXCR2 INHIBITORS | SANOFI-AVENTIS DEUTSCHLAND GMBH (DE) | 2008-04-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110184177-A1 | CXCR2 INHIBITORS | CXCR2, CXCR1, CXCR4 | MAPT 4665/4885NPC1 1259/4885EPHX2 227/4885 |
| US-20080090854-A1 | CXCR2 INHIBITORS | CXCR2, CXCR1, CXCR4 | MAPT 4665/4885NPC1 1259/4885EPHX2 227/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.